Velarion · Company Intelligence
CompBrief
Fiscal year 2025

Jane Chung — FY2025 total compensation $1,575,930

Jane Chung is Chief Executive Officer of Sutro Biopharma, Inc. (STRO). The company reported total compensation of $1,575,930 for fiscal year 2025.

01

Fiscal year 2025 compensation

Salary$652,000
Bonus$0
Stock awards$167,400
Option awards$245,280
Non-equity incentive plan$465,750
Pension and non-qualified deferred compensation$0
All other compensation$45,500
Total$1,575,930

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.

Cited to the compensation disclosure Sutro Biopharma, Inc. filed April 22, 2026, accession 0001193125-26-170354.

02

History — every fiscal year held

Fiscal yearRoleSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
FY2025Chief Executive Officer$652,000$0$167,400$245,280$465,750$0$45,500$1,575,930
FY2024Chief Executive Officer$560,000$0$454,000$169,360$182,000$0$78,000$1,443,360

Totals as disclosed in each year's own compensation disclosure for Sutro Biopharma, Inc..

03

Peer context

Peer-group chief executive median$3,512,673
Difference from that median$-1,936,743
Percentile within the disclosed peer group7th
Peers with a disclosed figure12

Medians and percentiles are computed across the peer group Sutro Biopharma, Inc. discloses in its own compensation disclosure.

04

The other named executive officers of Sutro Biopharma, Inc.

Named executive officerRoleFY2025 total
William NewellFormer Chief Executive Officer$1,671,311
Jane Chung this pageChief Executive Officer$1,575,930
Hans-Peter GerberChief Scientific Officer$942,902
Gregory ChowChief Financial Officer$854,522

The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Sutro Biopharma, Inc. compensation brief.

05

The company page

Jane Chung's compensation sits inside Sutro Biopharma, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.

The Sutro Biopharma, Inc. (STRO) compensation brief